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Background. The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti­
inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer's disease (AD). M eth odo logy/ 
P rincipal Findings. This double-blind, randomized, placebo-controlled trial was conducted between May 2000 and 
September 2005 in two hospitals in the Netherlands. 51 patients with mild to moderate AD were enrolled into the study. 
Patients received 100 mg indomethacin or placebo daily for 12 months. Additionally, all patients received omeprazole. The 
primary outcome measure was the change from baseline after one year of treatment on the cognitive subscale of the AD 
Assessment Scale (ADAS-cog). Secondary outcome measures included the Mini-Mental State Examination, the Clinician's 
Interview Based Impression of Change with caregiver input, the noncognitive subscale of the ADAS, the Neuropsychiatric 
Inventory, and the Interview for Deterioration in Daily life in Dementia. Considerable recruitment problems of participants 
were encountered, leading to an underpowered study. In the placebo group, 19 out of 25 patients completed the study, and 19 
out of 26 patients in the indomethacin group. The deterioration on the ADAS-cog was less in the indomethacin group 
(7.867.6), than in the placebo group (9.3610.0). This difference (1.5 points; CI -4 .5 -7 .5 ) was not statistically significant, and 
neither were any of the secondary outcome measures. C onclusions/Significance. The results of this study are inconclusive 
with respect to the hypothesis that indomethacin slows the progression of AD. Trial R egistration . ClinicalTrials.gov 
NCT00432081
Citation: de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, et al (2008) No Effect of One-Year Treatment with Indomethacin on 
Alzheimer's Disease Progression: A Randomized Controlled Trial. PLoS ONE 3(1): e1475. doi:10.1371/journal.pone.0001475
INTRODUCTION
Early indications that inflammation plays an important role in the 
pathogenesis of Alzheimer’s disease (AD) emerged in 1982, when 
complement factors were found in senile plaques. [1] Many studies 
followed that supported the inflammatory hypothesis, and 
evidence accumulated that anti-inflammatory drugs, in particular 
nonsteroidal anti-inflammatory drugs (NSAIDs) would either 
prevent, postpone or treat AD. [2] However, 25 years later, there 
is still no clinical evidence that NSAIDs have an effect in AD 
patients, nor is there incontrovertible evidence of the contrary.
In a small randomized controlled trial, the traditional NSAID 
indomethacin appeared to protect AD patients from cognitive 
decline. [3] Another small randomized controlled trial studying 
the effect of diclofenac/misoprostol in AD, found a nonsignificant 
trend of more advanced deterioration in the placebo group than in 
the diclofenac/misoprostol group. [4] A large randomized 
controlled trial with naproxen (440 mg/d) could not confirm the 
earlier observed trends. [5] Both pilot studies were hampered by 
high withdrawal rates in the treatment groups due to side effects. 
Low-dose naproxen was reasonably well tolerated.
The side effects of NSAIDs, e.g. gastrointestinal toxicity, have 
always been a major concern that limited their use. It was 
suggested that the beneficial actions of NSAIDs are linked to their 
ability to inhibit cyclooxygenase-2 (COX-2), while their side effects 
result from inhibition of COX-1. [6] However, randomized 
controlled trials with COX-2 selective NSAIDs (rofecoxib, 
nimesulide, and celecoxib) failed to show an effect on the 
progression of AD. [5,7-9] Consequently, the traditional nonse­
lective NSAIDs regained interest.
Apart from the promising, but never replicated, results of the 
initial indomethacin trial, there are also in vitro and animal model 
studies that support a possible therapeutic effect. Indomethacin 
inhibited amyloid ß (Aß)-induced neurotoxicity, [10-12] and 
decreased the production of Aß-protein, interleukin-6, interleukin- 
1, nitric oxide, and prostaglandin E2 in a variety of cultured cells. 
[13-18] Furthermore, indomethacin was found to have anti- 
amyloidogenic effects in vitro; The formation of Aß fibrils was 
dose-dependently inhibited by indomethacin. [19] In rats, 
indomethacin attenuated microglial infiltration, and improved
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lipopolysaccharide-induced amnesia. [20,21] In a transgenic 
mouse-model of AD-like amyloidosis (Tg2576), indomethacin 
suppressed brain levels of prostaglandins, [22] and reduced Aß 
levels in cortex and hippocampus. [22,23] This amyloid burden 
lowering effect was confirmed by other investigators using a 
combination of indomethacin and vitamin E to treat Tg2576 mice.
[24]
Supported by these data, particularly by the prior trial that 
suggested a therapeutic benefit as well as by its potential Aß 
lowering effect, we hypothesized that indomethacin may retard the 
clinical progression of AD.
METHODS
The protocol for this trial and supporting C O N SO R T  checklist 
are available as supporting information; see Protocol S1 (Dutch 
version), Protocol S2 (English version) and Checklist S1.
Participants
Patients were recruited from May 2000 to August 2004 at the 
Departm ent of Neurology and at the Memory Clinic, Departm ent 
of Geriatric Medicine of the Radboud University Nijmegen 
Medical Center, and at the Memory clinic of the Departm ent of 
Geriatric Medicine, Rijnstate Hospital, Arnhem, The Nether­
lands. Patients were eligible if they met the N IN C D S/A D R D A  
criteria for the clinical diagnosis of probable AD, [25] had mild or 
moderate dementia as measured by a Mini-Mental State 
Examination (MMSE) [26] score between 10 and 26 inclusive, 
and were living at home or in a home for the elderly. Patients had 
to be supported by a reliable caregiver, who accompanied them to 
each clinic visit in order to provide information about the patient’s 
functional status, and who would ensure that the participants took 
their test medication.
Patients were excluded if they had a history or current evidence 
of peptic ulceration; history of gastric surgery or gastrointestinal 
bleeding; severe and unstable cardiovascular disease; severe 
pulmonary disease; renal failure (serum creatinine greater than 
200 mmol/l); clinically significant liver disease (plasma aspartate 
and alanine aminotransferase levels three times the upper limit of 
normal); poorly controlled diabetes mellitus; hypersensitivity to 
NSAIDs or aspirin; alcohol abuse; or advanced, severe and 
unstable disease of any type (other than AD), that might interfere 
with evaluations during the study, including a medical condition 
which should be expected to progress, recur, or change to such an 
extent that it might bias the assessment of the clinical or mental 
status of the patient, or put the patient at special risk. Also, patients 
taking the following concomitant medications were excluded, 
because of a possible interaction with indomethacin; aspirin, 
coumarin derivatives, angiotensin converting enzyme inhibitors, 
loop diuretics, and long-term use of other NSAIDs or corticoste­
roids (more than two months immediately before study entry). 
Intake of the following medication was not allowed during the 
study because of a possible effect on cognition; estrogen 
replacement therapy, deprenyl, vitamin E, neuroleptics and 
anticholinergic medication. Patients using stable doses of cholin­
esterase inhibitors were eligible, with the provision that the dose 
should not be changed during the study. Cholinesterase inhibitors 
could not be initiated during the study.
Ethics
At both study sites, approval of the local institutional review 
board to perform the study was received. Informed consent was 
obtained from each patient and their legally acceptable represen­
tative.
Interventions
The study was a one-year, randomized, double-blinded, placebo­
controlled bicenter trial. After screening, patients were randomly 
assigned to receive 50 mg indomethacin twice daily or placebo 
twice daily for one year. In addition, patients in both treatment 
groups received omeprazole 20 mg once daily, to prevent 
gastrointestinal side effects.
Objectives
We tested whether indomethacin would have an effect on 
cognitive and behavioral dysfunction, as well as dysfunction of 
the activities of daily living, in patients with mild to moderate AD.
Outcomes
Efficacy was primarily assessed by the cognitive subscale of the AD 
Assessment Scale (ADAS-cog), [27] an instrument that evaluates 
memory, language, attention, reasoning, orientation, and praxis 
(range 0 to 70). Secondary outcome measures included the 
MMSE, [26] the Clinician’s Interview Based Impression of 
Change with caregiver input (CIBIC+), [28] the noncognitive 
subscale of the ADAS (ADAS-noncog), [27] the Neuropsychiatric 
Inventory (NPI), [29,30] including the NPI caregiver distress scale 
(NPI-D), [31] and the Interview for Deterioration in Daily life in 
Dementia (IDDD). [32] The IDDD is a caregiver-based measure, 
which consists of 20 concretely worded items that reflect the 
initiative to perform, and the actual performance of self-care and 
more complex activities.
Cognitive and behavioral assessments were performed at 
baseline, and at weeks 26 and 52. Safety assessments included 
vital signs and the recording and rating of any adverse event by the 
investigator (weeks 4, 8, 12, 26, 38, and 52), physical examination 
(baseline, week 26, and 52), and routine hematology and chemistry 
blood tests (baseline, week 4, 8, 26, and 52).
Sample size
The primary hypothesis tested was that indomethacin would be 
superior to placebo in retarding cognitive decline as measured on 
the ADAS-cog after one year of treatment. We aimed at 80% 
power to detect a 3-point difference in the change in ADAS-cog 
score after one year between patients who received indomethacin 
and those who received placebo. ADAS-cog data from previous 
studies were used in the power calculations for the initial trial, and 
an SD of 7 was assumed. This yielded a estimated sample size of 
67 to be evaluated per group. Since an overall dropout rate of 20% 
was anticipated, the required sample size was 80 patients per 
group.
Randomization -  Sequence generation
The statistician provided computer-generated lists of random 
numbers allocating patients in a 1:1 ratio to receive indomethacin 
or placebo. For each center, a separate randomization list was 
provided.
Randomization -  Allocation concealment
Randomization codes were held by the pharmacy of the Radboud 
University Nijmegen Medical Center that labeled and dispensed 
all trial medication. Allocation was concealed from all investigators 
and patients.
Randomization -  Implementation
Eligible patients were allocated to a randomization number in the 
same order they were enrolled in the trial at both trial sites. At
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each visit, patients received a supply of medication (indomethacin 
or placebo) by the pharmacy, labeled with their randomization 
number.
Blinding
The indomethacin and placebo tablets were of identical appearance. 
Neither the patients nor the investigators knew which treatment they 
received or dispensed. The blinding process remained complete until 
all data was entered in the trial database and the accuracy of the data 
and the database was confirmed. Afterward, the database was 
forwarded to the statistician for analysis.
Statistical methods
The changes from baseline in the groups were compared using 
analysis of covariance with the baseline results of each assessment 
as a covariate. In an additional analysis, gender and age were 
added as covariates. Two-sided p values and 95% confidence 
intervals were calculated. The primary efficacy analysis was 
conducted on the observed values. In addition, the last observation 
carried forward (LOCF) approach was used.
RESULTS
Participant flow and recruitment
Figure 1 illustrates the flow of patients through the study protocol. 
The study was discontinued prematurely after four years, due to 
difficulties with the enrollment of patients into the study. Based on 
an inclusion rate of approximately thirteen patients per year, eight 
more years of enrollment would have been necessary to complete 
this study. Taking into account scientific, organizational, and 
financial reasons, the decision was made to discontinue the study. 
Eventually, fifty-one patients were included in the trial, about one- 
thirds of the number originally anticipated. Most patients were 
enrolled at the Memory Clinic, Departm ent of Geriatric Medicine 
of the Radboud University Nijmegen Medical Center (n = 46), 
with an inclusion rate of one out of every five to six patients 
diagnosed with AD. The remainder of patients was enrolled at the 
outpatient clinic of the Departm ent of Neurology of the Radboud 
University Nijmegen Medical Center (n = 3), and at the D epart­
ment of Geriatric Medicine of the Rijnstate Hospital, Arnhem 
(n = 2).
Numbers analyzed
Twenty-five patients were randomly assigned to the placebo 
group, and twenty-six patients to the indomethacin group. 
Completion rates were 19 of 25 patients (76%) in the placebo 
group, and 19 of 26 patients (73%) in the indomethacin group. 
One patient in the indomethacin group discontinued the study in 
week 48 due to caregiver issues, but completed all week 52 
evaluations. The predom inant reasons for prem ature study 
discontinuation were adverse events (n = 6) in the indomethacin 
group, and withdrawal of consent (n = 2) in the placebo group. 
None of the patients that withdrew from the study due to adverse 
events did complete their follow-up assessments, however all other 
available assessment data were included in the analysis.
Baseline data
Treatm ent groups were similar with respect to demographic and 
baseline clinical characteristics, except for gender distribution 
(table 1); in the placebo group 24% of patients were male, and in 
the indomethacin group 46% of patients. No significant differences 
were found between baseline assessment scores. Nevertheless, 
baseline NPI, NPI-D, and ADAS-noncog scores were higher in the
indomethacin group, suggesting that patients in this group had 
more behavioral problems.
Outcomes, estimation, and ancillary analyses
The effect of treatm ent on primary and secondary outcome 
measures is shown in table 2. The decrease in mean ADAS-cog 
score after one year of therapy was 1.5 points less in the 
indomethacin group (7.867.6) compared to the placebo group 
(9.3610.0), however this was not statistically significant (CI - 4 .5 ­
7.5). W hen using the LOCF approach to analyze the difference in 
change in ADAS-cog score, or when gender and age were 
included as covariate in the analysis, the results were similar to the 
primary analysis (data not shown).
The decline of secondary outcome measures after six months or 
one year of treatm ent did not show statistically significant 
differences between groups either (table 2). Additional analysis, 
using the LOCF approach, showed similar results.
Adverse Events
Blood test abnormalities, abnormalities found during physical 
examination, and adverse events reported on case report forms 
were grouped into categories for analysis. Adverse events that 
occurred in at least two patients in either treatm ent group are 
listed in table 3. Patients in the indomethacin group had more 
frequent adverse events. Dyspepsia, epigastic pain, or abdominal 
distress or pain, were reported more frequently in the placebo 
group (n = 3), than in the indomethacin group (n = 1). In both 
groups, there were no reports of serious gastrointestinal adverse 
events, such as gastroenteritis, ulceration or bleeding. Nausea, 
dizziness, and hyperglycemia were more common in the 
indomethacin group, whereas diarrhea, constipation, and head­
ache, were more common in the placebo group. Weight loss, 
defined as 5 percent or more loss of body weight, was seen in three 
patients in the indomethacin group, and in one patient in the 
placebo group. New cases of hypertension were reported more 
frequently in the indomethacin group (5 out of 22 non­
hypertensive patients at baseline; 23%), than in the placebo group 
(2 out of 18 non-hypertensive patients at baseline; 11%). Despite 
these cases of elevated blood pressure, the change in mean arterial 
pressure (MAP) during the trial was not significantly different 
between groups; MAP increased 2.5610.6 (m ean6SD) m m Hg in 
the indomethacin group, and decreased 1.269.5 m m Hg in the 
placebo group (p = 0.20).
Serious adverse events were also more common in the 
indomethacin group (n = 5) than in the placebo group (n = 1; 
table 4), and reason for study withdrawal (table 4). In the 
indomethacin group, blood tests revealed a considerable elevation 
of creatinine levels (>1.5 times the upper limit of normal) in three 
patients, without clinical symptoms. All three patients had 
abnormal creatinine clearance rates before entering the trial, 
and one of these patients had a history of nephrectomy. After 
discontinuation of the study, serum creatinine levels returned to 
their previous levels. Blood tests also revealed increased levels (>3 
times the upper limit of normal) of alanine aminotransferase, and 
aspartate aminotransferase in one patient in the indomethacin 
group, without clinical symptoms. Liver function tests normalized 
within four weeks after study discontinuation. Nine days after 
enrollment in the study, one patient in the indomethacin group 
had a lacunar stroke. Evaluation after four months of recovery 
revealed only minor disabilities (increased memory impairment 
and irritability). Death occurred in one patient in the placebo 
group after 38 weeks of study participation. The cause of death of 
this patient is unknown.
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Figure 1. Trial profile.
doi:10.1371/journal.pone.0001475.g001
DISCUSSION
Interpretation
In this study, indomethacin 50 mg twice daily did not show any 
statistically significant effects on the progression of dementia in 
patients with mild to moderate AD during a 1-year period, as
Table 1. Baseline characteristics of the study population by 
treatment group.
Characteristics Placebo (n = 25)
Indomethacin 
(n = 26)
Men/women 6/19 12/14
Age (SD), years 72.2 (9.0) 72.7 (6.9)
Education level (SD), range 1 to 5* 2.7 (0.9) 2.4 (1.3)
$1 APOE e4 allele, n (%) 11 (44%) 13 (50%)
Disease duration (SD), months 31.1 (19.6) 32.9 (17.4)
Use of cholinesterase inhibitor, n (%) 2 (8,0%) 2 (7.7%)
MMSE score (SD) 20.2 (3.9) 19.1 (4.1)
ADAS-cog score (SD) 19.7 (8.8) 20.2 (8.3)
ADAS-noncog score (SD) 2.8 (2.7) 3.5 (3.6)
NPI score (SD) 7.1 (6.7) 11.2 (12.0)
NPI-D score (SD) 5.6 (4.5) 7.7 (7.3)
IDDD score (SD) 21.2 (12.8) 22.8 (13.7)
leve l 1 is primary school only; level 5 is university level.
MMSE =  Mini-Mental State Examination; ADAS-cog =  cognitive subscale of the 
Alzheimer's Disease Assessment Scale; ADAS-noncog = noncognitive subscale 
of the ADAS; NPI =  Neuropsychiatric Inventory; NPI-D = caregiver distress scale 
of the NPI; IDDD = Interview for Deterioration in Daily life in Dementia. 
doi:10.1371/journal.pone.0001475.t001
measured by testing of cognition, behavior, and activities of daily 
living, and by overall clinical global impression.
Although our study included more patients than the earlier trials 
with indomethacin and diclofenac/misoprostol, the number of 
included patients was still too small. [3,4] Thus, the study was 
clearly underpowered, resulting in very wide confidence intervals; 
The confidence interval for the ADAS-cog was 12 points (range -  
4.5 to 7.5). This means that the difference between the groups 
should have been at least 6 points to reach statistical significance.
Generalizability
The enrollment of patients was hampered by the extensive 
exclusion criteria, especially the exclusion of patients using aspirin, 
angiotensin converting enzyme inhibitors or loop diuretics. The 
institutional review board specifically imposed this criterion, since 
interaction of these drugs with indomethacin might aggravate the 
occurrence of side effects of indomethacin. Not only did patient 
enrollment suffer from these strict criteria, it is also responsible for 
another limitation of the study; O ur study population was a highly 
selected group of AD patients, with no or minor cardiovascular 
comorbidity, and thus not representative of the average AD 
population.
Overall evidence
By its nature our study cannot prove that anti-inflammatory drugs 
in general and indomethacin in particular are ineffective. 
However, the study outcome is consistent with earlier trials that 
investigated prednisone, hydroxychloroquine, and various selec­
tive and non-selective NSAIDs in similar designs; All these studies 
failed to demonstrate a beneficial effect on disease progression. 
[4,5,7-9,33,34] These failures may have been due to the 
pharmacokinetic or pharmacological properties of the drugs being
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Table 2. Mean change from baseline of outcome measures, and difference in scores between the placebo and indomethacin 
group, after six months and one year of treatment.
Placebo group mean change from 
baseline (SD)
Indomethacin group mean change from 
baseline (SD) Difference between groups* (95% CI)
Measure 6 months (n = 23) 1 year (n = 19) 6 months (n = 20) 1 year (n =1 9 ) 6 months 1 year
ADAS-cog 3.9 (4.5) 9.3(10.0) 4.8 (5.8) 7.8 (7.6) -0 .9  (-4 .1 -2 .2 ) 1.5 (-4 .5-7 .5)
ADAS-noncog -0 .3  (1.5) 1.6 (4.2) 1.5 (4.1) 3.8 (6.7) -1 .8  (-3 .9-0 .2) -2 .8  ( - 6.7-1.1 )
MMSE -2 .4  (3.6) -5 .4  (5.5) -2 .3  (3.2) -3 .4  (4.3) 0.1 ( - 1.9-2.1) 1.6 ( - 1.6-4.8)
NPI -0 .3  (4.9) 9.4 (14.0) 1.7 (14.0) 3.2 (18.1) -3 .6  (-10.1-2.9) 4.6 (-6 .6-15.8)
NPI-D -0 .9  (3.5) 6.5 (8.8) 0.7 (6.4) 1.4 (8.3) -2 .2  ( - 5.4-1.0) 4.6 (-1 .3-10.5)
IDDD 10.4 (8.3) 18.2 (14.8) 9.5 (14.4) 19.4 (13.8) 0.8 ( - 6.4-8.0) -1 .5  (-11.0-8.0)
CIBIC+ 5.3 (0.7) 5.7 (0.7) 5.1 (0.8) 5.6 (0.8) 0.2 (-0 .2 -0 .6 ) 0.1 (-0 .3 -0 .5)
"differences, adjusted for baseline (analysis of covariance).
Negative change in scores from baseline indicates improvement, with the exception of the MMSE score (positive change indicates improvement), and the CIBIC+ 
(higher score means worse compared to baseline).
Positive difference between groups means in favor of the indomethacin group, for all measures.
ADAS-cog = cognitive subscale of the Alzheimer's Disease Assessment Scale; ADAS-noncog = noncognitive subscale of the ADAS; MMSE = Mini-Mental State 
Examination; NPI = Neuropsychiatric Inventory; NPI-D = caregiver distress scale of the NPI; IDDD = Interview for Deterioration in Daily life in Dementia; CIBIC+ = Clinician's 
Interview Based Impression of Change with caregiver input. 
doi:10.1371/journal.pone.0001475.t002
used. But it may also be questioned whether anti-inflammatory 
treatm ent will ever be efficacious in treating symptomatic AD. 
Although they may have preventive effects, they may no longer be 
effective in patients with established disease.
Indomethacin in combination with omeprazole was reasonably 
well tolerated in this elderly population. There were no serious 
gastrointestinal tract events. Dyspepsia, epigastic pain, or abdom­
inal distress or pain were more common in the placebo group, and 
may have been caused by omeprazole, and not by indomethacin. 
However, elderly patients should be carefully monitored when
using indomethacin. Blood pressure should be checked regularly, 
and blood tests must be done before and during indomethacin 
treatment. In patients with elevated creatinine clearance, the 
administration of indomethacin should be avoided.
In conclusion, the results of this study are inconclusive with 
respect to the hypothesis that indomethacin slows the progression 
of AD. Owing to its limited statistical power, this study does not 
alter the conclusions from earlier trials that NSAIDs do not appear 
to be effective in altering the progression of symptoms in AD. 
Thus, treatm ent of AD patients with indomethacin should
Table 3. Adverse events that occurred in at least two patients in either treatment group.
Adverse event Placebo and omeprazole (n = 25) Indomethacin and omeprazole (n = 26)
Nausea 0 2
Diarrhea or constipation 3 2
Dyspepsia, epigastric or abdominal pain 3 1
Weight loss ($  5% during the study) 1 3
Headache 2 0
Dizziness 1 3
Hyperglycemia 1 2
Hypertension (new cases) 2 5
doi:10.1371/journal.pone.0001475.t003
Table 4. Serious adverse events.
Serious adverse event Placebo and omeprazole (n = 25) Indomethacin and omeprazole (n = 26)
Elevated creatinine*
Abnormal liver function tests{ 
Stroke (lacunar)
Death
>1.5  times the upper limit of normal. 
{ > 3  times the upper limit of normal. 
doi:10.1371/journal.pone.0001475.t004
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currently not be recommended, and further treatm ent trials with 
NSAIDs in AD patients should be thoroughly reconsidered. 
However, primary prevention trials with NSAIDs, in particular 
ibuprofen (in combination with omeprazole), are warranted to 
further investigate the effect of long-term NSAID use on risk of 
AD.
SUPPORTING INFORMATION
C hecklist S1 C O N SO R T  Checklist
Found at: doi:10.1371/journal.pone.0001475.s001 (0.05 MB 
DOC)
Protocol S1 Trial Protocol (Dutch)
Found at: doi:10.1371/journal.pone.0001475.s002 (0.26 MB 
DOC)
Protocol S2 Trial Protocol (English)
Found at: doi:10.1371/journal.pone.0001475.s003 (0.16 MB 
DOC)
ACKNOWLEDGM ENTS
We thank Arenda van Beek for data management, and David Burger, 
clinical pharmacist, for pharm aceutical support and monitoring.
Author Contributions
Conceived and designed the experiments: DD RJ W H  MJ M V BK. 
Performed the experiments: D D  RJ W H  MJ. Analyzed the data: D D  GB. 
W rote the paper: DD RJ M V  BK.
REFERENCES
1. Eikelenboom P, Stam  FC (1982) Im m unoglobulins and  com plem ent factors in 
senile plaques. A n im m unoperoxidase study. Acta N europathol Berl 57:
239-242.
2. M cG eer PL, M cG eer EG  (2006) NSAIDs and Alzheimer disease: Epidem io­
logical, anim al model and  clinical studies. N eurobiol Aging 28: 639-47.
3. Rogers J, K irby LC , H em pelm an SR, Berry D L, M cG eer PL, et al. (1993) 
Clinical trial of indom ethacin in A lzheimer’s disease. Neurology 43: 1609-1611.
4. Scharf S, M ander A, U goni A, V ajda F, Christophidis N  (1999) A  double-blind, 
p lacebo-controlled trial of d iclofenac/m isoprostol in A lzheim er’s disease. 
Neurology 53: 197-201.
5. Aisen PS, Schafer K A , G rundm an M , Pfeiffer E , Sano M , et al. (2003) Effects of 
rofecoxib or naproxen vs placebo on A lzheim er disease progression: a 
random ized controlled trial. JAM A 289: 2819-2826.
6. V ane J R , Bakhle YS, Botting R M  (1998) Cyclooxygenases 1 and 2. A nnu Rev 
Pharm acol Toxicol 38: 97-120.
7. Reines SA, Block GA, M orris J C , Liu G , Nessly M L, et al. (2004) Rofecoxib: no 
effect on A lzheim er’s disease in  a  1-year, random ized, blinded, controlled study. 
Neurology 62: 66-71.
8. Aisen PS, Schmeidler J ,  Pasinetti GM  (2002) R andom ized pilot study of 
nimesulide treatm ent in A lzheimer’s disease. Neurology 58: 1050-1054.
9. Soininen H , W est C , Robbins J ,  Niculescu L (2007) Long-term  efficacy and  
safety o f celecoxib in Alzheimer’s disease. D em ent G eriatr Cogn Disord 23: 
8-21.
10. Dzenko KA, W eltzien RB, Pachter JS  (1997) Suppression of A  beta-induced 
m onocyte neurotoxicity by antiinflam m atory compounds. J  N euroim m unol 80: 
6-12.
11. Fagarasan M O , Efthimiopoulos S (1996) M echanism  ofam yloid beta-peptide (1­
42) toxicity in PC12 cells. M ol Psychiatry 1: 398-403.
12. Fagarasan M O , Aisen PS (1996) IL-1 and  anti-inflammatory drugs m odulate A 
beta cytotoxicity in PC12 cells. Brain Res 723: 231-234.
13. W eggen S, Eriksen J L , Das P, Sagi SA, W ang R , et al. (2001) A  subset of 
N SA ID s lower am yloidogenic A beta42 independently  o f cyclooxygenase 
activity. N ature 414: 212-216.
14. K adoyam a K , Takahashi Y, H igashida H , T anabe T , Yoshimoto T  (2001) 
Cyclooxygenase-2 stimulates production o f am yloid beta-peptide in neuroblas­
tom a x glioma hybrid N G108-15 cells. Biochem Biophys Res C om m un 281: 
483-490.
15. Blom M A, van Twillert M G , de Vries SC, Engels F , Finch C E , et al. (1997) 
N SAIDS inhibit the IL-1 beta-induced IL-6 release from  hum an post-m ortem  
astrocytes: the involvement o f prostaglandin E2. Brain Res 777: 210-218.
16. Bour A M , W estendorp R G , Laterveer J C , Bollen EL, R em arque EJ (2000) 
Interaction o f indom ethacin w ith cytokine production in  whole blood. Potential 
mechanism  for a brain-protective effect. Exp G erontol 35: 1017-1024.
17. H oozem ansJJ, Veerhuis R , Janssen I, Rozemuller AJ, Eikelenboom P (2001) 
Interleukin-1beta induced cyclooxygenase 2 expression and  prostaglandin E2 
secretion by hum an neuroblastom a cells: implications for Alzheimer’s disease. 
Exp G erontol 36: 559-570.
18. D u ZY, Li X Y  (1999) Inhibitory effects o f indom ethacin on interleukin-1 and 
nitric oxide production in rat microglia in vitro. Int J  Im m unopharm acol 21: 
219-225.
19. H irohata M , O no  K , N aiki H , Y am ada M  (2005) N on-steroidal an ti­
inflamm atory drugs have anti-amyloidogenic effects for A lzheim er’s beta­
amyloid fibrils in vitro. N europharm acology 49: 1088-1099.
20. N etland EE , N ew ton J L , M ajocha R E , T a te  BA (1998) Indom ethacin reverses 
the microglial response to am yloid beta-protein. N eurobiol Aging 19: 201-204.
21. M a T C , Zhu X Z (1997) Suppression o f lipopolysaccharide-induced im pairm ent 
o f active avoidance and  interleukin-6-induced increase of prostaglandin E2 
release in rats by indom etacin. A rzneim ittelforschung 47: 595-597.
22. Sung S, Y ang H , Uryu K, Lee EB, Zhao L, et al. (2004) M odulation o f nuclear 
factor-kappa B activity by indom ethacin influences A  beta levels but not A  beta 
precursor protein m etabolism in a  model o f A lzheimer’s disease. A m  J  Pathol 
165: 2197-2206.
23. Q uinn  J ,  M ontine T , M orrow  J ,  W oodw ard W R , K ulhanek D , et al. (2003) 
Inflam m ation and  cerebral amyloidosis are  disconnected in an  anim al model of 
Alzheimer’s disease. J  N euroim m unol 137: 32-41.
24. Yao Y, Chinnici C , T ang  H , Trojanowski J Q ,  Lee V M , et al. (2004) Brain 
inflamm ation and  oxidative stress in  a  transgenic mouse model ofAlzheimer-like 
brain  amyloidosis. J  N euroinflam m ation 1: 21.
25. M cK hann G, D rachm an D, Folstein M , K atzm an R, Price D, et al. (1984) 
Clinical diagnosis of Alzheimer’s disease: report o f the N IN C D S-A D R D A  W ork 
G roup under the auspices of D epartm ent of H ealth  and  H um an Services Task 
Force on A lzheimer’s Disease. Neurology 34: 939-944.
26. Folstein M F, Folstein SE, M cH ugh PR  (1975) ‘‘M ini-m ental state’’. A  practical 
m ethod for grading the cognitive state o f patients for the clinician. J  Psychiatr 
Res 12: 189-198.
27. Rosen W G , M ohs R C , Davis K L (1984) A  new  rating scale for A lzheimer’s 
disease. A m J  Psychiatry 141: 1356-1364.
28. K nopm an D S, K napp M J, G racon SI, Davis CS (1994) T he Clinician 
Interview-Based Impression (CIBI): a  clinician’s global change rating scale in 
A lzheimer’s disease. Neurology 44: 2315-2321.
29. Cumm ings JL , M ega M , Gray K , Rosenberg-Thom pson S, Carusi DA, et al. 
(1994) T he Neuropsychiatric Inventory: comprehensive assessment o f psycho­
pathology in dem entia. Neurology 44: 2308-2314.
30. K at M G , de Jonghe J F , A alten P, Kalisvaart CJ, Droes R M , et al. (2002) 
Neuropsychiatric symptoms o f dem entia: psychometric aspects o f the D utch 
Neuropsychiatric Inventory (NPI). Tijdschr G erontol G eriatr 33: 150-155.
31. K aufer D I, Cum m ings J L , Christine D , Bray T , Castellon S, et al. (1998) 
Assessing the im pact o f neuropsychiatric symptoms in A lzheimer’s disease: the 
Neuropsychiatric Inventory Caregiver Distress Scale. J  A m  G eriatr Soc 46: 
210-215.
32. Teunisse S, D erix M M  (1997) T he interview for deterioration in daily living 
activities in dem entia: agreem ent between prim ary and  secondary caregivers. Int 
Psychogeriatr 9 Suppl 1: 155-162.
33. Aisen PS, Davis K L, Berg J D , Schafer K , Cam pbell K , et al. (2000) A 
random ized controlled trial of prednisone in A lzheimer’s disease. A lzheimer’s 
Disease Cooperative Study. Neurology 54: 588-593.
34. V an  Gool WA, W einstein H C , Scheltens PK , W alstra GJ (2001) Effect of 
hydroxychloroquine on progression of dem entia in early Alzheim er’s disease: an 
18-month random ised, double-blind, placebo-controlled study. Lancet 358: 
455-460.
PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1475
